Aspire Biopharma Holdings, Inc.
ASBP
$8.87
-$0.38-4.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 388.86% | 15.46% | 217.08% | 350.55% | 417.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 214.03% | 16.55% | 177.62% | 432.93% | 725.49% |
| Operating Income | -206.14% | -14.57% | -176.98% | -432.05% | -725.49% |
| Income Before Tax | 36.00% | 79.78% | -514.82% | -759.50% | -1,944.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 36.00% | 79.78% | -514.82% | -755.52% | -1,944.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.00% | 79.78% | -514.82% | -755.52% | -1,944.69% |
| EBIT | -206.14% | -14.57% | -176.98% | -432.05% | -725.49% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 97.46% | 95.93% | -66.01% | -376.85% | -1,043.68% |
| Normalized Basic EPS | 94.14% | 66.92% | -66.01% | -379.10% | -833.50% |
| EPS Diluted | 97.46% | 95.93% | -66.01% | -376.85% | -1,043.68% |
| Normalized Diluted EPS | 94.14% | 66.92% | -66.01% | -379.10% | -833.50% |
| Average Basic Shares Outstanding | 2,425.30% | 395.89% | 270.43% | 79.57% | 78.70% |
| Average Diluted Shares Outstanding | 2,425.30% | 395.89% | 270.43% | 79.57% | 78.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |